ComparePhase IIPhase II
Tissue Repair
BPC-157 vs TB-500
A research-first comparison of two heavily discussed tissue-repair peptides with high anecdotal attention.
BPC-157
Tissue Repair
Injury recovery, gut healing, tendon and ligament repair
203 PubMed references44 human-tagged
TB 500
Tissue Repair
Tissue repair, wound healing, muscle recovery
16 PubMed references11 human-tagged
Side-by-side
| Signal | BPC-157 | TB 500 |
|---|---|---|
| Research angle | Gastrointestinal, tendon, ligament, wound models | Actin regulation, tissue repair, wound and muscle recovery discussion |
| Evidence maturity | Human evidence exists but public claims often outrun it | Less mature public evidence picture; related thymosin beta-4 literature matters |
| Public conversation | Very high injury-recovery and FDA-docket chatter | Often paired with BPC-157 in recovery stacks and access debates |
Sentiment Readout
Both are dominated by injury-recovery anecdotes, with BPC-157 more gut/tendon-coded and TB-500 more mobility/recovery-coded.
Regulatory Context
Both sit in a sensitive compounding and anti-doping context; FDA review signals should not be read as access approval.